DHR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Danaher Corporation presents a dichotomy between strong operational quality and poor valuation metrics. The deterministic baseline is weak, with a Piotroski F-Score of 4/9 (Stable) and a current price of $195.50 that significantly exceeds both the Graham Number ($91.62) and the Intrinsic Value ($129.26). While the balance sheet is exceptionally healthy with low debt/equity (0.37), the stock is trading at a steep premium. Despite a 'Strong Buy' analyst consensus and a high target price of $256.05, the bearish technical trend and insider selling suggest caution.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
DHR vs LLY: Head-to-Head Comparison
This page compares Danaher Corporation (DHR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.